All Updates

All Updates

icon
Filter
Partnerships
QurAlis and Eli Lilly enter exclusive license agreement to develop and distribute ALS and FTD therapeutics
Precision Medicine
Jun 3, 2024
Last week:
Partnerships
Geographic expansion
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Industry news
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

Jun 3, 2024

QurAlis and Eli Lilly enter exclusive license agreement to develop and distribute ALS and FTD therapeutics

Partnerships

  • QurAlis has partnered with Eli Lilly to develop and commercialize QurAlis' QRL-204, a splice-switching antisense oligonucleotide (ASO) designed to fix UNC13A function, focused on treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

  • According to the agreement, Eli Lilly will be granted global rights to develop and commercialize QRL-204 and other UNC13A-targeting compounds, for which QurAlis will receive an initial payment of USD 45 million along with possible future payments up to USD 577 million and royalties on net sales and equity investment. The agreement also includes a collaborative R&D program to identify and develop additional candidates targeting UNC13A, using QurAlis' proprietary FlexASO Splice Modulator Platform.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.